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beta-(1,6)-Branched beta-(1,3)-D-glucans like schizophyllan from the basidiomycete Schizophyllum commune excite various
immunostimulatory effects and have been clinically tested as adjuvants. Some of the glucans are also applicable in food or petrol
industry due to their viscosity and temperature stability in aqueous solution. Antibodies against these glucans could be used as
tool for analysis of glucan preparations or for further research of its bioactivity. Therefore, an immune phage display library was
constructed from mice immunized with schizophyllan. Three recombinant monoclonal antibodies were isolated from this library
by affinity selection (panning) on schizophyllan.Thehalf-maximal effective concentration (EC50) values for those antibodies varied
between 16.4 ngmL−1 and 21.3 ngmL−1. The clones showed binding specificity not only for schizophyllan but also for other beta-
(1,6)-branched beta-(1,3)-D-glucans of similar macromolecular structure. Denaturation of the secondary structure led to a reduced
antibody binding, indicating an epitope requiring the correct conformation of the triple helical structure of the glucans.
1. Introduction
A variety of fungal beta-(1,3)-D-glucans are described as sub-
stances with antitumoral and immunomodulating activities
[1]. One example is schizophyllan (SCH) that is produced as
extracellular polysaccharide by the basidiomycete Schizophyl-
lum commune [2–5]. Its bioactivity is based on the enhance-
ment of cell-mediated immune response with stimulation
of T lymphocytes and macrophages and improving cytokine
production [6–9].
The primary molecular structure of SCH consists of a
beta-(1,3)-D-glucan main chain with single beta-(1,6)-linked
glucose molecules at approximately every third glucose
monomer of the backbone [10, 11]. In aqueous solution
it forms the secondary structure of a triplex composed
of three twisted chains stabilized by hydrogen bonds with
single beta-(1,6)-linked glucose residues protruding outside
the helix backbone [12–15]. Differences in branching grade
and molecular weight are considered to be responsible for
variations in bioactivity [16–18]. In addition to its bioactivity,
SCH also has physical properties favorable for a use in food
and oil industry. Aqueous solutions of SCH are viscous and
show pseudoplastic flow behavior [19]. Furthermore, they
are stable at high temperature and in a broad pH range,
starting to denature at pH > 12 or >135∘C [15, 20, 21]. Since
SCH can be used for many applications, the generation of
antibodies would be of great value because they could be used
for quantitative trace analysis or for the investigation of the
role of particular conformations for glucan bioactivity.
The objective of this study was the generation of recom-
binant monoclonal antibodies (rAbs) against the beta-D-
glucan schizophyllan. Therefore, we constructed an antibody
phage display library from the lymphocytes of three mice
which had been immunized with proteinase K treated SCH
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(SCH-PK). After panning of this library for SCH-PK binding
antibody phage, we were able to derive three rAbs specificity
binding beta-(1,6)-branched beta-(1,3)-D-glucans with the
same secondary structure as SCH.
2. Materials and Methods
2.1. Chemicals. All chemicals were purchased from Sigma
Aldrich if not mentioned otherwise.
2.2. Preparation of beta-(1,6)-Branched beta-(1,3)-D-Glucans.
Following beta-(1,6)-branched beta-(1,3)-D-glucans were
prepared from biomass-free and stabilized (5 g L−1 formic
acid) culture supernatants: SCH (Schizophyllum commune
ATCC 38548), scleroglucan (Sclerotium rolfsii ATCC
15205), cinerean (Botrytis cinerea LU 14548), and fructican
(Monilinia fructigena ATCC 24976) [4, 22–24]. The
supernatants were diluted to 1.0 g L−1 glucan (volume
100mL) with water and adjusted to pH 7.5 with NaOH.
In the next step the glucan solutions were purified by
diafiltration with water (Vivaflow 50 R, MWCO 100,000,
Sartorius, Go¨ttingen, Germany) until the conductance of the
retentate dropped to 0 𝜇S cm−1.The glucan solution was then
reduced to 100mL and sterilized at 120∘C for 20 minutes.
Quantification was performed by mixing of 5mL glucan
solution with 15mL 2-propanol and incubation overnight
at 4∘C. The precipitated glucan was weighed after isolation
by centrifugation with 13,000×g at 4∘C as well as drying for
48 h at 50∘C under reduced pressure.
In addition to this schizophyllan preparation, commer-
cially acquired samples of schizophyllan from Contipro
Biotech (Dolnı´ Dobroucˇ, Czech Republik) and Actigum
CS 11 (scleroglucan) purchased from Degussa Construction
Polymers GmbH (Trostberg, Germany) were used.
2.3. Preparation of Proteinase K Treated Glucans. SCH addi-
tionally treated with proteinase K (SCH-PK) was used as
antigen for the isolation of antibodies. For its preparation,
biomass-free culture supernatant of S. commune was diluted
to 1.0 g L−1 glucan in 100mLwithwater and adjusted to pH 7.5
with NaOH. 2mL of 0.5mol L−1 CaCl
2
in 1mol L−1 Tris-HCl
(pH 7.4) and 1mL of 10% (w/v) sodium dodecyl sulfate were
added and the solution was incubated at 80∘C for 4 hours.
After cooling to 40∘C, 10mg of proteinase K was solved and
the solution incubated for 24 h at 40∘C under slight shaking.
The proteinase K treatment was stopped by incubation at
80∘C for 4 hours. The solution was diluted to 1 L with water,
cleared by centrifugation with 13,000×g for 1 h at 16∘C and
then processed as described above. The same procedure was
applied for culture supernatant of S. rolfsii.
2.4. Immunization of Mice and Library Construction. Three
mice (BALB/c, female, 7 weeks old) were immunized with
SCH-PK by intraperitoneal injection. Three injections were
applied in two-week intervals. Each injection consisted of
25 𝜇g of SCH-PK and 50 𝜇L of the adjuvant Magic Mouse
(Creative Biomart, New York, USA). Four weeks after the
third injection, three additional injections with 50 𝜇g of
SCH-PK and 100 𝜇L of PBS (phosphate buffered saline)
were applied over a period of three days to boost the B
cell proliferation. Two days later, the mice were sacrificed.
Their spleens were isolated and homogenized in TRIzol LS
Reagent (Life technologies, Carlsbad, USA).
A volume equal to 1 × 107 of homogenized leucocytes
was used to isolate the RNA with the Direct-zol MiniPrep
kit (Zymo Research, Irvine, USA). The isolation of the
rearranged genes for the antibody domains𝑉
𝐿
(variable light)
and 𝑉
𝐻
(variable heavy) and their cloning into the phage
display vector pHAL30 was carried out as described [25, 26].
The derived 𝑉
𝐿
sublibraries for lambda (V-LAMBDA) and
kappa (V-KAPPA) of each mouse were kept separately. The
six sublibraries were packaged with hyperphage [27].
2.5. Ethics Statement. The experimental protocols were car-
ried out in accordance with the Directive 2010/63/EU of the
European Parliament and the Council of the EuropeanUnion
of 22 September 2010 and all procedures were approved by
guidelines from the Animal Committee on Ethics in the
Care and Use of Laboratory Animals of TU Braunschweig,
Germany (Az §5 (02.05) TschB TU BS Az:33.42502-14-
005/08).
2.6. Immobilization of Schizophyllan onto Multiwell Plates.
For the antibody selection and ELISA experiments,
schizophyllan was immobilized to Carbo-BIND multiwell
plates (Corning, Corning, USA). The wells were filled
with 100 𝜇L of 10 𝜇gmL−1 SCH-PK in 10mmol L−1 acetate
buffer (pH 5.4) and the sealed plates were incubated at
37∘C overnight. The following day the wells were washed
10 times with water in an ELISA washer (HydroFlex,
Tecan, Ma¨nnedorf, Switzerland) and filled for storage
with 300 𝜇L PBS (8.0 g L−1 NaCl, 0.2 g L−1 KCl, 1.44 g L−1
Na
2
HPO
3
∗4H
2
O, 0.24 g L−1 KH
2
PO
4
, pH 7.4) containing
NaN
3
(0,2 g L−1) until use.
2.7. Selection of Recombinant Antibodies against SCH by
Antibody Phage Display. The rAbs were selected by panning
as described [28] from the pooled immune libraries with V-
LAMBDA (3×1010 colony forming units, cfu) and V-KAPPA
(3 × 1010 cfu) which had been preincubated for 1 h in blank
wells of a Carbo-BINDmultiwell plate. Plasmid preparations
(NucleoSpin Plasmid EasyPure, Macherey-Nagel, Du¨ren,
Germany) were derived from the E. coli clones which con-
tained a positive tested rAB and sent to Seqlab Sequence Lab-
oratories GmbH (Go¨ttingen, Germany) for sequencing. The
sequences were compared with mouse germline sequences
via the online sequence analysis tool IMGT/V-QUEST from
the International ImMunoGeneTics information system
(IMGT, http://www.imgt.org/) [29, 30].
2.8. Production and Purification of Isolated Antibodies as scFv-
Fc. For further characterization of the isolated rAbs, the
DNA encoding the scFv (single chain Fragment variable)
was subcloned into pCSE2.6-mIgG2c-Fc-XP via NcoI and
NotI (New England Biolabs, Ipswich, USA). The resulting
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scFv-Fc fusions (scFv fused with a murine Fc part) were
produced in HEK239-6E cells (National Research Council,
Biotechnological Research Institute, Montreal, Canada) as
described [31]. Briefly, cells were cultivated in chemically
defined medium FreeStyle F17 (Gibco, Thermo Fisher
Scientific, Waltham, USA) added by 1 g L−1 Pluronic F-68
(AppliChem, Darmstadt, Germany), 4mmol L−1 glutamine
(PAA Laboratories GmbH, Co¨lbe, Germany), and 25mg L−1
G418 (PAA Laboratories GmbH, Co¨lbe, Germany) at 37∘C,
110 rpm as well as 5% CO
2
in the atmosphere (Minitron,
Infors, Bottmingen, Switzerland). For transfection, 25𝜇g of
expression vector was used for 25mL culture (about 1.5 ×
106 cells mL−1) in a 125mL Erlenmeyer shake flask. 48 h after
transfection the culture was fed with 25mL fresh media and
1.25mL of 20% (w/v) tryptone N1 (Organotechnie S.A.S, La
Courneuve, France). The secreted scFv-Fc was purified from
the supernatant by affinity chromatography on a UNOsphere
SUPrA column (Biorad, Hercules, USA) and a Bio-Scale
Mini Bio-GelP-6 Desalting cartridge (Biorad, Hercules,
USA) in an automated Profinia system (BioRad, Hercules,
USA).The concentrations of the preparations were calculated
by their absorbance at 280 nm (NanoDrop 2000, Thermo
Fisher Scientific, Waltham, USA).
2.9. Titration ELISA. The half-maximal effective concentra-
tion (EC50) values of the produced scFv-Fc were determined
by titration ELISA (enzyme-linked immunosorbent assay)
using serial dilutions of the scFv-Fc in blocking solution
(2% (w/v) milk powder and 0.05% (w/v) Tween 20 in
PBS). ELISA was performed with SCH-PK loaded Carbo-
BIND multiwell plates (100 𝜇L well−1, 10 𝜇gmL−1). The plate
was blocked for 1 h at room temperature. The blocking
solution was discarded and 100 𝜇L of the scFv-Fc (in blocking
solution) was filled into the wells. After 1 h incubation, the
plate was washed for 3 times with PBST (0.05% (w/v) Tween
20 in PBS). Afterwards, 100 𝜇L well−1 peroxidase-conjugated
goat anti-murine Fc antibody (A0168, 1 : 40,000 in blocking
solution) was added and incubated for an additional 1 h.
The plate was then washed again for 3 times with PBST.
The color reaction was obtained by adding 100 𝜇L well−1
TMB solution (20 volumes TMB A (30mmol L−1 potassium
citrate, 0.5mol L−1 citric acid, pH 4.1) and 1 volume TMB B
(10mmol L−1 3,3󸀠,5,5󸀠-tetramethylbenzidine, 10% (v/v) ace-
tone, 90% (v/v) ethanol, 0.3% (v/v) H
2
O
2
)). The reaction
was stopped after 10min by addition of 100 𝜇L well−1 of
0.5mol L−1 H
2
SO
4
. The resulting absorption was measured
at 450 nm (reference wavelength 620 nm).
2.10. Competitive ELISA. Antigen specificity was evaluated
via competition of scFv-Fc binding to immobilized SCH-
PK by various soluble saccharides. Each scFv-Fc was used
in the concentration that resulted in 40% of the saturation
signal in the titration ELISA.Theywere preincubated in serial
dilutions of competitors (3.2 ngmL−1 to 1mgmL−1, blocking
solution as solvent) for 1 h before they were transferred to the
SCH-PK loaded Carbo-BIND plate. The further procedure
was done as described for titration ELISA. The following
substances were used as competitors: SCH-PK, SCH, scle-
roglucan (S. rolfsii), cinerean, fructican, scleroglucan of Scle-
rotium glucanicum (DSM 2159), SCH fromContipro Biotech,
Actigum CS 11 (scleroglucan), laminarin, dextran, xanthan,
laminarihexaose (Megazyme, Wicklow, Ireland), beta-(1,6)-
D-gentiobiose, yeast extract (Ohly, Hamburg, Germany), and
glucose. Furthermore, NaOH treated SCH-PK was used,
due to its changed secondary structure (triplex denatured
to single chains, partial formation of cyclic structures). It
was derived by adding NaOH until a pH of 13.8 had been
reached and it was neutralized with HCl before use. Solutions
of denatured SCH-PK and SCH were also used. Both were
prepared by overnight incubation of SCH-PK and SCH
with endoglucanase from Penicillium funiculosum (kindly
provided by Erbslo¨h, Geisenheim, Germany) at 50∘C. The
endoglucanase was inactivated by heating up to 80∘C for 20
minutes.
All investigations were carried out at least in three
independent experiments.
3. Results and Discussion
3.1. Selection and Identification of Recombinant Antibodies
against Proteinase K Treated Schizophyllan. The goal of this
study was the generation of a rAb that binds to the beta-
(1,6)-branched beta-(1,3)-D-glucan schizophyllan of Schizo-
phyllum commune. We constructed a library from three
immunized mice to increase the possibility of isolating the
desired antibody. Since we wanted to derive an antibody
which binds to the glucan itself, rather to possible residual
protein contaminants, we used proteinase K treated SCH for
immunization. The proteinase K treatment should eliminate
proteins or other polypeptides that could be associated
with the glucan. From each mouse, two sublibraries were
derived, V-LAMBDA and V-KAPPA, which were pooled and
used for the antibody selection on SCH-PK loaded Carbo-
BIND multiwell plates. The surface of Carbo-BIND plates
is functionalized with hydrazide-groups. Hydrazides react
selectively with aldehyde groups under acidic conditions
which allowed the covalent binding of the reducing end from
SCH. Preliminary experiments showed that multiwell plates
with other surface properties did not work and sometimes
led to the generation of antibodies against adsorbed protein
impurities (data not shown).
After three rounds of panning, 92 of the enriched
antibody clones from each library were selected and the
respective soluble scFv-fragments were tested by ELISA for
binding to SCH-PK. 60 clones of the V-KAPPA library
showed specific binding; 10 of those clones with the highest
signal and highest difference to the signal of the negative con-
trol were sequenced. Three individual antibodies (JoJ48C11,
JoJ48F1, and JoJ49D10) with high sequence similarities were
identified. The heavy chain of each recombinant antibody
contains the variable gene IGHV1-7∗01, the diversity gene
IGHD1-1∗02, and the joining gene IGHJ2∗01. The variable
gene of the light chain for each antibody is IGKV4-59∗01.
For the antibodies JoJ48C11 and JoJ49D10 the joining gene
is IGKJ5∗01. IGKJ2∗07 was assigned to JoJ48F1.
http://publikationsserver.tu-braunschweig.de/get/64847
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Figure 1: Titration ELISA for analysis of the binding of the
isolated antibodies in bivalent form (scFv-Fc). Dilution series of
the antibodies from 0.095 pM to 945 nM were applied to SCH-PK
coated or uncoated Carbo-BIND plates.
3.2. Binding Strength of the Isolated Antibodies as scFv-Fc. The
three isolated rAbswere produced as scFv-Fc consisting of the
scFv fused to a murine IgG2c Fc part.The scFv-Fc format is a
bivalent antibody comparable to a full length IgG [31].
The rAbs were analyzed as scFv-Fc by titration ELISA.
Serial dilutions from 0.095 pM to 945 nM antibody were
applied on SCH-PK loaded and blankCarbo-BINDmultiwell
plates. The resulting data (Figure 1) showed almost identical
sigmoidal increase of the absorbance signal with increasing
scFv-Fc concentration in a half-logarithm plot for all three
antibodies. The half-maximal effective concentration (EC50)
was derived froma regression of absorbance signal against the
logarithm of antibody concentration by a sigmoidal function
(3 parameters). The EC50 correlates with the affinity of the
rAbs to SCH-PK [32]. The EC50 values are 155 ± 4 pM, 201
± 7 pM and 189 ± 9 pM for JoJ48C11, JoJ48F1, and JoJ49D10,
respectively.
3.3. Antibody Specificity. Analysis for the specificity in anti-
gen recognition was performed by a competitive approach.
The rAbs were incubated in solutions of different saccha-
rides or yeast extract before they were added to SCH-PK
loaded Carbo-BIND plates. For illustration, only the data of
JoJ49D10 are presented in Figure 2 because the results of
JoJ48C11 and JoJ48F1 were very similar.
The expected decrease of signal with increasing concen-
trations of SCH-PK in solution was observed for each rAb.
Furthermore, a decrease of signal was also found, as expected,
for nontreated SCH and the other beta-(1,6)-branched beta-
(1,3)-D-glucans like scleroglucan of S. rolfsii, cinerean, fruc-
tican, scleroglucan of S. glucanicum, proteinase K treated
scleroglucan, SCH (Contipro Biotech), and Actigum CS 11
(scleroglucan from Degussa Construction Polymers). The
scleroglucans and cinerean have a high similarity to SCH.
They possess the same primary molecular structure, con-
sisting of beta-(1,6)-linked D-glucose at every third glucose
of the beta-(1,3)-D-glucan main chain. Additionally, they
form also a triple helix as secondary structure [22, 23].
Fructican has a slightly different primary structure with beta-
(1,6)-bound D-glucose alternating at every second or third
glucose of the main chain [18, 24]. Its secondary structure is
considered to be a triplex as well. The recognition of those
glucans reveals a specificity of the rAbs not just for SCH but
also for other high molecular beta-(1,6)-branched beta-(1,3)-
D-glucans forming a triple helix.
Only a slight signal decrease at higher concentrations of
NaOH treated SCH-PKwas observed for each rAb.Due to the
NaOH treatment of SCH-PK, the glucan possesses a changed
macromolecular structure. The triple helix denatures into
single chains when the pH exceeds 13 [21]. Neutralization
of those SCH solutions leads to minimal renaturation to
the triple helical structure, while random coiled structures
are primarily formed [33]. This observation indicates that
the native triple helical structure is an important factor
for the recognition of the beta-(1,6)-branched beta-(1,3)-D-
glucanmolecule by the selected antibodies, since the primary
structure is not changed. The residual interaction could be
explained by occasional formation of triple helical stretches
inside the random coils and small amounts of renatured SCH
triplex [34].
JoJ48C11 and JoJ48F1 showed a slight interaction with
laminarin of Laminaria digitata. It consists of a beta-(1,3)-
D-glucan main chain with an occasional beta-(1,6)-bound
D-glucose and exists predominantly as linear molecule with
only approximately 5% occurring as triplex [35]. This obser-
vation further corroborates the assumption that the triple
helical structure is a key factor for rAb recognition.
Xanthan, dextran, laminarihexaose, beta-(1,6)-D-
gentiobiose, glucose, yeast extract, and glucanase treated
SCH/SCH-PK did not inhibit the binding of any of
the three antibodies to SCH-PK. Xanthan consists of
a beta-(1,4)-D-glucan backbone with beta-(1,3)-linked
beta-D-mannose-(1,4)-beta-D-glucuronic acid-(1,2)-alpha-
D-mannose side chain at every second glucose and forms
a double helix in aqueous solution [36]. Dextran is an
alpha-(1,6)-D-glucan with around 5% branching points at
alpha-(1,3)-position to a single glucose or a dimer of glucose
[37]. The results with xanthan and dextran indicate that
there are no unspecific interactions of the rAbs with high
molecular polysaccharides of different glycosidic linkages.
D-glucose and laminarihexaose (linear hexamer of beta-
(1,3)-bound D-glucose) and beta-(1,6)-D-gentiobiose (dimer
of beta-(1,6) bound D-glucose) also did not interfere with the
binding of the rAbs to SCH, indicating that D-glucose and
the beta-(1,6) or beta-(1,3) linkage of D-glucose alone are not
sufficient to provide binding by the rAbs. Yeast extract was
the complex ingredient of the medium for the production of
SCH. The test assured that the antibodies do not bind to a
residual impurity from the media in the used SCH solution.
Incubation of SCH with endoglucanase degrades it into
D-glucose monomers and oligomers. An interference of the
glucanase treated solutions was not observed and indicated
that degraded saccharides or other released components,
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Biotechnology Research International 5
SCH-PK
SCH (Contipro biotech)
SCH
Actigum™ CS11 (scleroglucan)
Scleroglucan-PK (S. rolfsii)
Laminarin
Scleroglucan (S. rolfsii)
Cinerean
Fructican
Scleroglucan (S. glucanicum)
Glucose
Yeast extract
SCH-PK, glucanase treated
Xanthan
Dextran
SCH, glucanase treated
SCH-PK, NaOH treated
Laminarihexaose
Gentiobiose
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Ab
so
rb
an
ce
 (4
50
nm
–6
2
0
nm
), 
no
rm
al
iz
ed
10−2 10−1 100 101 102 10310−3
Competitor (휇g mL−1)
Figure 2: Competitive ELISA of antibody JoJ49D10 for the characterization of antigen specificity. JoJ49D10 (scFv-Fc) was preincubated in
dilutions of different carbohydrates or yeast extract ranging from 10 ngmL−1 to 1mgmL−1 before being added to SCH-PK loadedCarbo-BIND
multiwell plates. The absorbance signals were normalized by division with the absorbance of respective samples without competitor.
including potential protein impurities, were not recognized
by the antibodies.
The experiments showed that the triple helical structure
of the glucans is the essential factor for antibody recognition.
It is assumed that the spatial arrangement of the beta-
(1,6)-linked D-glucose residues is an important part of the
antibody binding epitope. The beta-(1,6)-branching ratio of
the glucan also affects the reactivity of the antibody binding.
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Table 1: EC50 values of competitors which are recognized by the recombinant antibodies.
Competitors EC50 values [𝜇gmL
−1]
JoJ48C11 JoJ48F1 JoJ49D10
SCH-PK 25.1 ± 1.8 24.9 ± 3.7 7.8 ± 1.0
SCH 36.2 ± 4.6 29.4 ± 6.4 9.1 ± 0.6
Scleroglucan (S. rolfsii) 54.4 ± 2.0 52.3 ± 5.3 19.9 ± 2.8
Scleroglucan (PK-treated) 83.1 ± 5.1 54.5 ± 13.2 34.0 ± 1.2
Cinerean 4.2 ± 0.2 4.7 ± 0.7 0.5 ± 0.1
Fructican 6.8 ± 0.4 8.8 ± 1.8 1.0 ± 0.2
Scleroglucan (S. glucanicum) 3.1 ± 0.2 1.7 ± 0.5 0.4 ± 0.1
SCH (Contipro biotech) 8.2 ± 1.2 7.0 ± 1.2 1.1 ± 0.2
Actigum CS11 (Scleroglucan) 88.5 ± 5.0 74.2 ± 14.4 31.7 ± 1.5
Fructican possesses a higher degree of branching points but
does not influence the reactivity of the antibodies compared
to the different types of schizophyllan and scleroglucan as
well as cinerean. Laminarin shows not only a low occurrence
of triplex structure but also a lower degree of branching
which could be also responsible for the weak antibody
binding. This leads to the additional conclusion that besides
the triplex the beta-(1,6)-branching degree also influences
antibody reactivity.
With the gained datasets the EC50 values of the com-
peting glucans (except for NaOH treated SCH-PK and
laminarin) were calculated from the signal reduction and
compared as value for the binding strength of the antibodies
to the glucans (all data shown in Table 1). In dependence of
the rAb, the EC50 values for SCH-PK varied between 7.8 to
25.1 𝜇gmL−1. The proteinase K untreated SCH offered jointly
increased EC50 of 9.1 to 36.2𝜇gmL−1.The lowest EC50 values
of 0.4 to 3.1 𝜇gmL−1 and consequently the greatest inter-
ference were observed for scleroglucan from S. glucanicum.
The difference of EC50 values between the glucans can be
explained by different molecular size distribution, occur-
rence of additional macromolecular structures depending
on the production strains, and downstream processing. For
example, SCH and SCH-PK showed similar EC50 values
because both derived from the same production batch and
were identically purified except proteinase K treatment. The
commercial SCH purchased by Contipro Biotech, produced
and purified in unknown procedures, showed lower EC50
data.
In summary, the results suggest that the generated rAbs
recognize a conformational epitope requiring an intact triple
helical secondary structure of beta-(1,6)-branched beta-(1,3)-
D-glucans with an optimal branching degree of one beta-
(1,6)-bound D-glucose attached to approximately every three
glucose units of the main chain. As a consequence, the
rAbs not only are specific for SCH but also bind to similar
beta-(1,6)-branched beta-(1,3)-D-glucans with triple helical
structure.
Reports about the generation of an antibody against
SCH already exist. Tabata et al. reported the generation of
an antiserum from immunized rabbits [38]. Other authors
described the isolation of a monoclonal antibody against
SCH from immunized mice via hybridoma technology [39].
That antibodywas also able to bind other beta-(1,6)-branched
beta-(1,3)-D-glucans like scleroglucan and even bound to
laminaritetraose, a tetramer of beta-(1,3)-bound D-glucose.
Investigations of monoclonal antibodies generated with
other beta-(1,3)-D-glucans also exist with binding specifici-
ties to more than one glucan [40–43]. Just recently, two
antibodies against the extracellular beta-glucan of Pleurotus
ostreatuswere isolated [44, 45].This glucan exhibits the same
molecular structure as SCH. It is assumed as well that these
antibodies recognize and bind to a common conformational
epitope.The difference to our investigations is that we proved
the triple helical arrangement as an essential element for
the recognition by the rAbs. Furthermore, it was verified by
proteinase and endoglucanase treatment that the rAbs bind to
the sugar structure and not to associated proteins or peptides.
4. Conclusion
In this report the successful generation of three recombinant
glucan antibodies is described.Theywere selected for binding
to the beta-(1,6)-branched beta-(1,3)-D-glucan schizophyllan
of Schizophyllum commune froman immune library via phage
display. In addition to schizophyllan, the antibodies recognize
other beta-(1,6)-branched beta-(1,3)-D-glucans that possess a
triplex as secondary structure and similar branching degree
as schizophyllan. As other helical arrangements and lower
order oligomers or monomers were not bound, the antigenic
epitope is assumed to be conformational. Therefore, the
antibodies can be used as analytical tools for the specific
detection of schizophyllan and similar beta-(1,6)-branched
beta-(1,3)-D-glucans with triple helical arrangement.
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